Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor- kappa B

M Goto, K Yamada, K Katayama and I Tanaka

Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.

(2E)-3-[5-(2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonyl-2- propenoic acid (E3330), is a novel agent with hepatoprotective activity. We report the effect of E3330 on transcriptional activation of tumor necrosis factor (TNF)-alpha gene and on nuclear factor (NF)- kappa B activation. Nuclear run-on experiments showed that E3330 decreases transcriptional activation of TNF-alpha gene induced by lipopolysaccharide (LPS) stimulation in human peripheral monocytes. To investigate the inhibitory mechanisms, we constructed a secreted-type placental alkaline phosphatase (PLAP) reporter gene whose transcription is controlled by a 1.4-kb human TNF-alpha promoter. A stable transformant of the PLAP reporter gene derived from human monocytic cell line showed very little activity on the promoter before stimulation, whereas LPS stimulation led to a dramatic increase in PLAP activity. E3330 inhibited this induced promoter activity in a dose- dependent manner. There are four putative NF-kappa B binding sites (kappa B-1, kappa B-2, kappa B-3, kappa B-4) in human TNF-alpha promoter. By using mutated promoter-PLAP plasmids, we established that these NF-kappa B sites were necessary for induction of TNF-alpha transcription on stimulation with LPS. A gel retardation experiment with synthetic double-stranded oligonucleotides showed that activated NF-kappa B consisting of p50/p65 heterodimer bound to all four putative NF-kappa B DNA probes, suggesting that all four putative NF-kappa B recognition sites play an important role in inducible TNF-alpha expression. E3330 decreased activated NF-kappa B in nuclei, suggesting that E3330 inhibits NF-kappa B activation and/or translocation of the nuclei. Western blotting analysis with anti-I kappa B-alpha antibody indicated that E3330 inhibited degradation of I kappa B-alpha, which is an inhibitory protein of NF-kappa B, in LPS-stimulated monocytes. E3330 may suppress the production of active oxygen species serving as common messengers to activate NF-kappa B.

Volume 49, Issue 5, pp. 860-873, 05/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				Z. Zhong, M. Froh, H. D. Connor, X. Li, L. O. Conzelmann, R. P. Mason, J. J. Lemasters, and R. G. Thurman Prevention of hepatic ischemia-reperfusion injury by green tea extract Am J Physiol Gastrointest Liver Physiol, October 1, 2002; 283(4): G957 - G964. [Abstract] [Full Text] [PDF]

				S. Hoshi, M. Goto, N. Koyama, K.-i. Nomoto, and H. Tanaka Regulation of Vascular Smooth Muscle Cell Proliferation by Nuclear Factor-kappa B and Its Inhibitor, I-kappa B J. Biol. Chem., January 14, 2000; 275(2): 883 - 889. [Abstract] [Full Text] [PDF]

				M. Baba, M. Okamoto, and H. Takeuchi Inhibition of Human Immunodeficiency Virus Type 1 Replication in Acutely and Chronically Infected Cells by EM2487, a Novel Substance Produced by a Streptomyces Species Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2350 - 2355. [Abstract] [Full Text]

				M. L. Rose, C. A. Rivera, B. U. Bradford, L. M. Graves, R. C. Cattley, R. Schoonhoven, J. A. Swenberg, and R. G. Thurman Kupffer cell oxidant production is central to the mechanism of peroxisome proliferators Carcinogenesis, January 1, 1999; 20(1): 27 - 33. [Abstract] [Full Text] [PDF]